Twelve representatives of the anti-drug units of the National Police of eleven Latin American countries participated in a training seminar on special investigative techniques, which took place in Rome (Italy) from December 11 to 15, 2023, at the headquarters of the Central Anti-Drug Services Directorate (DCSA) of the Italian Ministry of the Interior. The course was organized by the COPOLAD III Program in cooperation with the DCSA as part of a best practices exchange activity that took place virtually during the year and in which participating Latin American countries had the opportunity to present the state of their legislation and their experience in special investigative techniques.
The training days included information on the Italian police system on special investigative techniques, exchange of experiences from Italy on knowledge and experiences on special operations in the fight against drug trafficking with a focus on the international context, controlled deliveries and new investigative techniques to combat drug trafficking through telematic channels. In addition, case studies on closed investigations were included, ranging from initial information to the authorization of undercover activities and, finally, arrests. The classes also focused on special operations to combat trafficking in chemical precursors and new chemical substances.
Guardia di Finanza
During the exchange the Central Investigation Service for Organized Crime (SCICO) of the Guardia di Finanza also presented its experience in the field of special operations. COPOLAD III is particularly focused on strengthening financial investigations and the fight against drug money laundering as one of the most efficient ways to fight organized crime.
The COPOLAD III program will continue through 2024 to support the exchange of experiences with Latin American and Caribbean countries wishing to strengthen their capacities in the fight against international drug trafficking. In addition to focusing on training reinforcement and work guides in regional organizations such as GAFILAT, GAFIC or AIAMP and the exchange of practices on drug precursors.
